ArticlemBio2019
Dynamic Emergence of Mismatch Repair Deficiency Facilitates Rapid Evolution of Ceftazidime-Avibactam Resistance in Pseudomonas aeruginosa Acute Infection.
Open access · goldAbstract readCase Reports
In one paragraph
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Emergence ofbioRxiv : the preprint server for biology · 2025Article
- Article
- Azithromycin represses evolution of ceftazidime/avibactam resistance by translational repression ofJournal of bacteriology · 2025Article
- Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy.Infectious diseases and therapy · 2025Article
- Experimental evolution ofMicrobiology spectrum · 2025Article
- Rapid and Integrated Bacterial Evolution Analysis unveils gene mutations and clinical risk of Klebsiella pneumoniae.Nature communications · 2025Article
- Transcriptional diversification in a human-adapting zoonotic pathogen drives niche-specific evolution.Nature communications · 2025Article
- Mutational signature analysis predicts bacterial hypermutation and multidrug resistance.Nature communications · 2025Article
- Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance.Nature reviews. Microbiology · 2024Review
- Monitoring of Pseudomonas aeruginosa mutational resistome dynamics using an enrichment panel for direct sequencing of clinical samples.EBioMedicine · 2024Article
- Genomic Comparative of Pseudomonas aeruginosa Small Colony Variant, Mucoid and Non-mucoid Phenotypes Obtained from a Patient with Cystic Fibrosis During Respiratory Exacerbations.Current microbiology · 2024Article
- Battling Salmonella enteritidis infections: integrating proteomics and in vivo assessment of Galla Chinensis tannic acid.BMC veterinary research · 2024Article
- The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity ofmBio · 2024Article
- Characterization ofAntimicrobial agents and chemotherapy · 2023Article
- Mutators can drive the evolution of multi-resistance to antibiotics.PLoS genetics · 2023Article
- Hypermutator strains of Pseudomonas aeruginosa reveal novel pathways of resistance to combinations of cephalosporin antibiotics and beta-lactamase inhibitors.PLoS biology · 2022Article
- Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa.Microbiology spectrum · 2022Article
- Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Mutators Enhance Adaptive Micro-Evolution in Pathogenic Microbes.Microorganisms · 2022Review
- An evolutionary explanation for antibiotics' association with increased colon cancer risk.Evolution, medicine, and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Pavel P KhilDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Augusto Dulanto ChiangLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Fredrick, Maryland, USA.
Jonathan HoDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Jung-Ho YounDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Jamie K LemonDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Juan Gea-BanaclocheExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Karen M FrankDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Mark PartaClinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Fredrick, Maryland, USA.
Robert A BonomoCWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA.
John P DekkerDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA john.dekker@nih.gov.
National Institutes of Health Clinical Center · USNational Institute of Allergy and Infectious Diseases · USFrederick National Laboratory for Cancer Research · USNational Cancer Institute · USUniversity School · US
Funding
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIDDK NIH HHS P30 DK089507
Abstract
Strains of
Indexed as
DNA Mismatch RepairAcute DiseaseAnti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDirected Molecular EvolutionDrug CombinationsDrug Resistance, Multiple, BacterialFatal OutcomeHumansMicrobial Sensitivity TestsMutationPseudomonas aeruginosaPseudomonas InfectionsRespiratory SystemWhole Genome SequencingAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug Combinationsantimicrobial agentsbacterial evolutionceftazidime-avibactamhost-pathogen interactionshypermutatormicrobial genomicsmismatch repairPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.